The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Featured here, the Balance Sheet for GlaxoSmithKline Pakistan Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 ...

Featured here, the Income Statement (earnings report) for GlaxoSmithKline Pakistan Ltd, showing the company's financial performance from operating and non operating activities such as revenue ...

Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...